Bayer AG BAYRY recently announced that the FDA had accepted its supplemental new drug application (sNDA) seeking approval for ...

Bayer's mineralocorticoid receptor antagonist (MRA) Kerendia hit the mark as a treatment for a common form of heart failure in the FINEARTS-HF study, setting up regulatory approvals, but there is ...

Bayer announced today that data from 13 new analyses from across the KERENDIA® (finerenone) comprehensive clinical trial program will be presented at the American College of Cardiology (ACC) 74th ...

Bayer's 2024 annual results showed a 2.2% sales decline, with only free cash flow improving significantly. Read why BAYZF ...

Bayer has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its kidney-disease drug Kerendia in certain people with heart failure.

The company is working to expand the labels of its key drugs, Nubeqa and Kerendia, which should boost growth. Successful development of additional drugs is imperative for Bayer amid multiple ...

The company is working to expand the labels of its key drugs, Nubeqa and Kerendia, which should boost growth. Successful development of additional drugs is imperative for Bayer amid multiple ...

Bayer announced today that data from 13 new analyses from across the KERENDIA® (finerenone) comprehensive clinical trial program will be presented at the American College of Cardiology (ACC ...